Long-term risk of sepsis among survivors of acute kidney injury

Abstract

Many prior studies have shown that, in critically ill patients, acute kidney injury (AKI) commonly occurs in association with sepsis and its presence portends an increased likelihood of poor outcomes. In contrast, few studies have focused specifically on the influence of AKI on the long-term risk of developing sepsis. In a previous issue of Critical Care, a population-based cohort study by Lai and colleagues reported a long-term increased risk of severe sepsis for patients surviving beyond 90 days following hospitalization with an episode of AKI requiring renal replacement therapy. While the pathophysiologic mechanisms that underpin this finding remain to be elucidated and causality cannot be proven, this study suggests that severe AKI confers long-term susceptibility to infection and focuses further attention on the critical importance of long-term surveillance for survivors of severe AKI. Further mechanistic and clinical studies are required to more precisely define the extent and duration of any increased risk of severe sepsis beyond which a need for ongoing renal replacement therapy following AKI might be associated. Nonetheless, this novel study by Lai and colleagues could lead to a number of important new avenues for clinical inquiry, such as whether it might be possible to identify those most susceptible to severe sepsis after AKI and, ultimately, whether such episodes might be preventable.

In a previous issue of Critical Care, Lai and colleagues describe a population-based cohort study evaluating the risk of severe sepsis following hospitalization associated with an episode of severe acute kidney injury (AKI) requiring renal replacement therapy (RRT) [1]. Using a large administrative database over a 10-year period, patients with severe AKI receiving RRT who survived to at least 90 days after hospital discharge were matched to those without severe AKI and followed for approximately 4 years for the occurrence of severe sepsis. The adjusted risk of developing severe sepsis prompting hospitalization was approximately twofold higher among those having had severe AKI compared with those not having had AKI (incidence rate of 6.84 vs. 2.32 per 100 person-years). Importantly, even among survivors with severe AKI who recovered kidney function to become dialysis independent, the adjusted risk of severe sepsis remained 50 to 70% higher compared with matched patients with no history of AKI.

AKI remains a widespread complication of acute illness, occurring in one in five adults and one in three children in association with an acute hospitalization [2]. Trends from observational data provide compelling evidence that the incidence of AKI continues to grow. While mortality has concomitantly decreased, more patients are ultimately suffering the long-term sequelae of AKI [3]. These sequelae include increased long-term risks of death, chronic kidney disease (CKD), progression to end-stage kidney disease, reduced quality of life and excess resource utilization [4,5].

Prior data have shown that AKI in critical illness most commonly occurs in association with sepsis and that its presence clearly worsens the risk of adverse outcomes [6]. However, fewer studies have focused specifically on any increased risks imposed by AKI for the downstream development of sepsis and consequent morbidity and mortality [7-11]. One of the earliest studies to show an increased risk of sepsis after AKI was performed in a cohort of hospitalized patients suffering AKI following radiocontrast procedures [11]. Among nonsurvivors, 45% developed a new episode of sepsis. The risk of nosocomial infection is higher among patients developing AKI after cardiac surgery [10]. Similarly, nosocomial infections occur more commonly among critically ill patients with severe AKI requiring RRT compared with matched controls [7,9]. A recent cohort study noted that sepsis after any AKI occurred in 40% of critically ill patients after a median 5 days [8]. Among critically ill patients with severe AKI receiving RRT, 13.4% of nosocomial infections occurred after discontinuation of RRT [9]. Sepsis after AKI portends a higher risk of RRT utilization and death and higher resource utilization [8,10]. Indeed, among nonsurvivors hospitalized with AKI, sepsis was the most common attributable cause of death, occurring in 41% [12].

These data clearly establish AKI as an immediate and short-term risk factor for the development of nosocomial infections and sepsis. This specific short-term risk among critically ill patients would appear understandable; however, the precise pathophysiologic mechanisms whereby AKI increases susceptibility for sepsis remains incompletely understood. There is probably a complex interplay of modifying factors including premorbid conditions that are also associated with higher risk of infection, such as genetics (for example, gene polymorphisms in inflammatory mediators), older age and comorbidities (for example, CKD, cancers), as well as more proximate factors including acute immune dysregulation, acute organ dysfunction, and treatment-related risks (for example, mechanical ventilation, hemodialysis catheter).

The data described by Lai and colleagues do not inform about the short-term risk of severe sepsis after AKI [1]. Instead, their study specifically evaluated the longer-term risk of severe sepsis conditional on survival to 90 days after index hospitalization. While nonmodifiable risk factors such as genetics, age, comorbidity and ongoing treatment-related risks are probably still contributing factors, the biologic mechanisms whereby AKI confers longer-term susceptibility to infection and sepsis are unknown. Nonetheless, the AKI and infection susceptibility association is plausible given that acute kidney insults are known to induce changes in gene regulation, oxidative stress, inflammation, leukocyte trafficking, and apoptosis and to incite systemic and distal organ injury [13].

While the idea that AKI independently confers increased risk of severe sepsis long after the occurrence of AKI is conceptually appealing, there are some caveats to consider. The hypothesis posited by Lai and colleagues is that AKI confers a sustained susceptibility to the development of new infections or severe sepsis through persistent immune suppression or senescence. While the study did show an increased risk of severe sepsis for survivors who recovered from AKI, the risk of severe sepsis among RRT-dependent survivors may largely be explained by RRT dependence itself. Sepsis remains a leading cause of morbidity and mortality among end-stage kidney disease patients: the rate of sepsis for US chronic hemodialysis patients was recently reported to be 282 per 1,000 patient-years [14]. Similarly, persistent nondialysis-requiring CKD could serve to confound any association between AKI and increased susceptibility to sepsis for those who recovered to become dialysis independent. Maladaptive repair mechanisms after AKI and incident CKD have been shown to modify the long-term risk of developing severe sepsis [15,16].

The study by Lai and colleagues has appropriately focused attention on the critical importance of long-term surveillance of survivors of AKI and may ultimately generate a number of important additional avenues of inquiry. If the risk of downstream severe sepsis is increased among survivors of severe AKI, can we identify those most susceptible and are such episodes amenable to preventative interventions? First, additional mechanistic and clinical studies are needed to better define the nature, magnitude and duration of the risk of severe sepsis following AKI, independent of the risks conferred by either CKD or end-stage kidney disease that requires ongoing RRT.

Abbreviations

AKI: Acute kidney injury; CKD: Chronic kidney disease; RRT: Renal replacement therapy.

Competing interests

The authors declare that they have no competing interests.

See related research by Lai et al., http://ccforum.com/content/17/5/R231

Acknowledgements

SMB is supported by a Canada Research Chair in Critical Care Nephrology and Clinical Investigator Award from Alberta Innovates – Health Solutions.